Sana Biotechnology (SANA) Amortization of Deferred Charges (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Amortization of Deferred Charges data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 10.52% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (up 9.68% YoY), and the FY2025 full-year result was $9.2 million, down 5.27% from the prior year.
• Amortization of Deferred Charges improved to $2.5 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $3.4 million in Q2 2023 to a low of $2.0 million in Q2 2024.
• A 5-year average of $2.7 million and a median of $2.6 million in 2022 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges surged 113.61% in 2022 and tumbled 39.75% in 2024, its largest moves.
• Tracing SANA's Amortization of Deferred Charges over 5 years: stood at $3.2 million in 2022, then declined by 0.4% to $3.2 million in 2023, then tumbled by 32.59% to $2.2 million in 2024, then increased by 9.68% to $2.4 million in 2025, then advanced by 3.22% to $2.5 million in 2026.
• Business Quant data shows SANA's Amortization of Deferred Charges at $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.